COMy 2019 | Second interim analysis of the EMN02 trial
Michele Cavo
Michele Cavo, MD, of Bologna University School of Medicine, Bologna, Italy, discusses the second interim analysis of the EMN02 trial (NCT01208766), which is the largest academic trial so far that aims to compare upfront transplant vs. standard dosing and consolidation vs. no consolidation for multiple myeloma. This interview was recorded at the Controversies in Multiple Myeloma (COMy) 2019 meeting held in Paris, France.
Similar topics
Related videos

Myeloma XI trial: increased progression-free survival
Charlotte Pawlyn

Pivotal STORM study: selinexor for penta-refractory multiple myeloma
Joshua Richter

Current challenges for multiple myeloma therapy: 2, 3, 4-drug combinations
Joshua Richter

Multiple myeloma musings: highlights from 2018 data
Joshua Richter

An exciting era for CAR T-cell therapy
Mohamad Mohty
More from Michele Cavo